Utilizing a discovery platform developed by co-founder Dr. Sohail Tavazoie, a Rockefeller professor and a medical oncologist at Memorial Sloan-Kettering Cancer Center, Rgenix is working on an approach designed radically to change cancer treatment by generating first-in-class therapeutics that target key nodes in cancer progression. The firm's proprietary discovery platform is based on innovations in cancer biology that enable the identification and validation of novel post-transcriptionally regulated targets. Rgenixs productive approach has yielded multiple novel targets to date across several cancer types for which the company is developing drugs, and its scientific approach has led to the discovery of novel therapeutic targets and first-in-class drugs for several cancer sub-types, including melanoma, colorectal cancer and triple-negative breast cancer, among others. The aim is to discover and develop safe, effective, and commercially viable therapies that will transform the lives of cancer patients by treating metastatic disease.
